drugset / Trial / NCT04556773
A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
DESTINY-Breast 08 will investigate the safety, tolerability, PK and preliminary anti-tumour activity of T-DXd in combination with other therapies in patients with Metastatic HER2-low Advanced or Metastatic Breast Cancer
Timeline
- Start
- 2020-12-17
- Primary completion
- 2023-08-16
- Completion
- 2026-06-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anastrozole | Other / unclassified | 1 mg | Oral |
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Subject | Capivasertib | Small molecule | 400 mg | Oral |
| Subject | Durvalumab | Monoclonal antibody | 1120 mg | Intravenous |
| Subject | Fulvestrant | Small molecule | 500 mg | Intramuscular |
| Subject | Paclitaxel | Small molecule | 80 mg/m2 | Intravenous |
| Subject | Trastuzumab deruxtecan | Monoclonal antibody | 5.4 mg/kg | Intravenous |